Acrivon Therapeutics Inc. is a biopharmaceutical company that is focused on developing novel therapeutics for the treatment of cancer. The company is based in San Diego, California, and was founded in 2020.
Acrivon Therapeutics is focused on developing small molecule inhibitors of the protein kinase CK1ɛ, which is a promising therapeutic target for the treatment of various types of cancer. The company's lead product candidate, AC-1204, is a potent and selective inhibitor of CK1ɛ that has demonstrated anti-tumor activity in preclinical studies.
The company's technology platform is based on a deep understanding of the biology of CK1ɛ and its role in cancer. By targeting this protein kinase with small molecule inhibitors, Acrivon Therapeutics believes it can develop therapies that are effective against a wide range of cancers, including those that are resistant to currently available treatments.
The global oncology market is expected to reach $237.8 billion by 2026, according to a report by Grand View Research. With its focus on developing innovative cancer therapies, Acrivon Therapeutics is well-positioned to capitalize on the expanding market.
Acrivon Therapeutics is led by a team of experienced professionals with a deep understanding of drug development and commercialization. The company's management team has a proven track record of success in the biopharmaceutical industry, and is committed to delivering value to its investors through a disciplined investment approach.
Acrivon Therapeutics is a biopharmaceutical company that is focused on developing novel therapeutics for the treatment of cancer. With a strong technology platform and a promising lead product candidate, the company is well-positioned to deliver value to its investors in the years ahead.